Datapoint: Latest Patent Ruling Protects Imbruvica Until 2032

AbbVie and Johnson & Johnson last week won a patent lawsuit in favor of their oncology drug Imbruvica, which now won’t see generic competition until at least 2032. The legal battle against Alvogen and Natco Pharma began in 2019. Imbruvica, which launched in 2014, is approved to treat several cancers, including chronic lymphocytic leukemia, mantle cell lymphoma and non-Hodgkin lymphoma. Under the pharmacy benefit, Imbruvica holds covered or better status for 71% of all insured lives.

SOURCE: MMIT Analytics, as of 9/1/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 27

Datapoint: FDA Approves First Interchangeable Humira Biosimilar

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 26

Datapoint: Oscar Partners With Colorado Health Systems in Statewide Expansion Effort

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today